AXIM® Biotechnologies Appoints New Chief Executive Officer
January 08, 2019 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Jan. 08, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced the...
First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis
January 03, 2019 07:30 ET
|
Biogen Inc.
Study will provide the first randomized, controlled efficacy and safety data of every-six-week dosing for natalizumab CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- The first patient has been...
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
December 17, 2018 07:30 ET
|
Biogen Inc.; Alkermes plc
DUBLIN, Ireland and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application...
First Descents Expands Programming to Serve Young Adults with Multiple Sclerosis
October 25, 2018 09:00 ET
|
Velocity Global
Denver, CO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- After 17 years of helping to improve the lives of young adults with cancer through activities like kayaking, rock climbing and surfing, non-profit First...
Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis
October 11, 2018 07:30 ET
|
Biogen Inc.
Evidence supports potential of serum neurofilament light (sNfL) as clinically useful biomarker in MS; Biogen and Siemens Healthineers collaborate to develop sNfL blood testReal-world data add to the...
Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
October 03, 2018 09:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemIntellectual property around pipeline targeting endocannabinoid...
Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care
October 02, 2018 07:30 ET
|
Biogen Inc.
New research further supports the long-term efficacy and well-characterized safety of leading MS productsNovel data generation initiatives aim to improve outcomes and support the continued move toward...
Q Therapeutics Receives Orphan Drug Designation for Transverse Myelitis
September 26, 2018 06:00 ET
|
Q Therapeutics, Inc.
FDA DESIGNATION WOULD PROVIDE 7 YEARS OF MARKET EXCLUSIVITY UPON MARKET APPROVAL OF Q-CELLS® SALT LAKE CITY, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Q Therapeutics, Inc., a developer of clinical-stage...
Aphios Pharma LLC Announces Reg. CF Private Placement Offering
September 17, 2018 08:00 ET
|
Aphios
WOBURN, Mass., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Aphios® Pharma LLC is pleased to announce the launch of a private placement offering in accordance with Regulation Crowdfunding (Reg. CF) adopted...
AXIM® Biotechnologies to Present at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology
August 15, 2018 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that the Company will be...